The Pharmaceutical Industry and Access to Medicines in India

Lofgren, Hans 2013, The Pharmaceutical Industry and Access to Medicines in India. In Lofgren, Hans (ed), The politics of the pharmaceutical industry and access to medicines : world pharmacy and India, Social Science Press, New Delhi, India, pp.1-23.

Attached Files
Name Description MIMEType Size Downloads

Title The Pharmaceutical Industry and Access to Medicines in India
Author(s) Lofgren, Hans
Title of book The politics of the pharmaceutical industry and access to medicines : world pharmacy and India
Editor(s) Lofgren, Hans
Publication date 2013
Chapter number 1
Total chapters 13
Start page 1
End page 23
Total pages 23
Publisher Social Science Press
Place of Publication New Delhi, India
Keyword(s) pharmaceutical industry
access to medicines
drug regulation
multinational companies
public healthTRIPS
Summary Pharmaceutical policy in India as elsewhere is shaped by conflicting economic and social interests and opposing values and priorities. Tensions can be understood as revolving around the contradiction between use value and exchange value in the production of medicinal drugs as commodities, as per Marx’s original analysis. The use value of medicines – if safe and efficacious, of good quality, and prescribed and consumed appropriately – is the prevention, cure or alleviation of ill-health and disease. Health policy is – or should be – aimed at optimising the use value of medicines. For this purpose government agencies administer regulatory oversight of the manufacturing, marketing and distribution of medicines. Drugs made available to patients are expected to meet adequate safety, quality and efficacy standards, but regulation to ensure such standards is subject to controversy in most countries. This is a domain where definition and interpretation of scientific-technological principles and criteria is infused by partiality and bias grounded in social and material interests, as evidenced by recurrent debates about industry ‘capture’ of regulatory agencies, including the world’s most regulator, the US Food and Drug Administration (Angell 2005; Law 2006). In India, a Parliamentary Committee Report in 2012 depicted the Central Drugs Standard Control Organisation (CDSCO) as dysfunctional and influenced inappropriately by the exchange value perspective of manufacturers (Parliamentary Standing Committee on Health and Welfare 2012). The clash between use and exchange value perspectives is starkly illustrated by cases of products known to cause more harm than good, particularly common in poorly regulated markets such as India’s, as shown by Srinivasan & Phadke.
ISBN 9788187358664
Language eng
Field of Research 160510 Public Policy
160606 Government and Politics of Asia and the Pacific
160508 Health Policy
Socio Economic Objective 940299 Government and Politics not elsewhere classified
HERDC Research category B1 Book chapter
ERA Research output type B Book chapter
HERDC collection year 2013
Copyright notice ©2013, Socla Science Press
Persistent URL

Connect to link resolver
Link to Related Work
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 418 Abstract Views, 6 File Downloads  -  Detailed Statistics
Created: Tue, 18 Dec 2012, 10:09:26 EST by Hans Lofgren

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact